Results 11 to 20 of about 4,900 (222)

Comparative Safety of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1-RAs) in Type 2 Diabetes and Chronic Weight Management: A Real-World Data Study. [PDF]

Pharmacoepidemiol Drug Saf
ABSTRACT Purpose This study assessed serious clinical outcomes comparing glucagon‐like peptide 1 receptor agonists (GLP‐1‐RAs) with sodium glucose co‐transporter 2 inhibitors (SGLT2‐Is) in patients with type 2 diabetes (T2DM) and patients without diabetes using two chronic weight management (CWM) regimens.
Hurwitz SR, Lanes S, Quimbo T, Papazian A, White J, Fisher V, Cziraky MJ, Crowley MJ, Willey VJ.   +8 more
europepmc   +2 more sources

Dissolution Assay of Bupropion/Naltrexone Hydrochloride Salts of Bilayer Composition Tablets Following the Development and Validation of a Novel HPLC Method. [PDF]

Materials (Basel), 2022
Apostolidi A, Protopapa C, Siamidi A, Vlachou M, Dotsikas Y.   +4 more
europepmc   +3 more sources

A Randomized, Blinded, Placebo-Controlled Crossover Study of the Pharmacokinetics and Pharmacodynamics of Naloxone, Naltrexone, and Nalmefene in Methadone-Sedated Working Dogs. [PDF]

J Vet Pharmacol Ther
ABSTRACT A randomized, blinded, placebo‐controlled crossover study was performed with eight professional working dogs to evaluate the pharmacokinetics and pharmacodynamics of three opioid reversal agents. Following sedation with 1 mg kg−1 methadone HCl IV, dogs were randomly assigned to receive naloxone, naltrexone, or nalmefene at 0.1 mg kg−1 IM, or ...
Mills T, Robinson MA, Barr C, Stefanovski D, You Y, Proctor R, Seizova K, Mallikarjun A, Otto CM.   +8 more
europepmc   +2 more sources

Simultaneous Transdermal Delivery of Buprenorphine Hydrochloride and Naltrexone Hydrochloride by Iontophoresis [PDF]

Molecular Pharmaceutics, 2019
The opioids buprenorphine hydrochloride (BUP) and naltrexone hydrochloride (NTX) show promise as a combination treatment for addiction, but no means of delivering the two compounds in one medicine currently exist. In this paper, we report sufficient input rates of both these drugs from one iontophoretic transdermal drug delivery system.
Sarah F. Cordery, Stephen M. Husbands, Christopher P. Bailey, Richard H. Guy, M. Begoña Delgado-Charro   +4 more
openaire   +3 more sources

Neuropsychological functioning in buprenorphine maintained patients versus abstinent heroin abusers on naltrexone hydrochloride therapy

Human Psychopharmacology: Clinical and Experimental, 2009
AbstractRationaleMethadone and buprenorphine are among the most widely employed pharmacological treatments currently available for opioid addiction. Cognitive effects of buprenorphine in abstinent heroin abusers are nevertheless far from being understood.MethodsNeuropsychological performance of 18 buprenorphine‐maintained patients (BMP) was evaluated ...
Lambros, Messinis, Epameinondas, Lyros, Virginia, Andrian, Paraskevi, Katsakiori, George, Panagis, Vasileios, Georgiou, Panagiotis, Papathanasopoulos   +6 more
openaire   +3 more sources

Microneedle-Assisted Percutaneous Delivery of Naltrexone Hydrochloride in Yucatan Minipig: In Vitro–In Vivo Correlation [PDF]

Molecular Pharmaceutics, 2013
Although microneedle-assisted transdermal drug delivery has been the subject of multiple scientific investigations, very few attempts have been made to quantitatively relate in vitro and in vivo permeation. The case of naltrexone hydrochloride is not an exception.
Mikolaj, Milewski, Kalpana S, Paudel, Nicole K, Brogden, Priyanka, Ghosh, Stan L, Banks, Dana C, Hammell, Audra L, Stinchcomb   +6 more
openaire   +3 more sources

High-performance liquid chromatography-based analytical techniques for simultaneous determination of Naltrexone hydrochloride (NTX) and Bupropion hydrochloride (BUP): a comprehensive review [PDF]

Discover Applied Sciences
AbstractThe confluence of Bupropion Hydrochloride and Naltrexone Hydrochloride within a composite pharmaceutical formulation has garnered the prestigious endorsement of the U.S. Food and Drug Administration (FDA) for its targeted application in addressing the pervasive issue of obesity. Naltrexone hydrochloride, a semi-synthetic opioid compound, exerts
Sehrish Zehra, Muhammad Asad Saeed, M. Zaman, Sadia Hassan, null Fazal-Ur-Rehman   +4 more
openaire   +2 more sources

A multicenter, primary-care-based, open-label study to assess the success of converting opioid-experienced patients with chronic moderate-to-severe pain to morphine sulfate and naltrexone hydrochloride extended-release capsules using a standardized conversion guide

Journal of Pain Research, 2015
Beatrice Setnik,1 Carl L Roland,1 Kenneth W Sommerville,1,2 Glenn C Pixton,1 Robert Berke,3,4 Anne Calkins,5 Veeraindar Goli1,2 1Pfizer Inc, 2Duke University Medical Center, Durham, NC, USA; 3Family Health Medical Services PLLC, Mayville, 4Department of ...
Setnik B, Rol, CL, Sommerville KW, Pixton GC, Berke R, Calkins A, Goli V   +7 more
doaj   +4 more sources

Naltrexone Hydrochloride [PDF]

, 2020
National Cancer Institute
openaire   +2 more sources

Inhibitory effects of the selective μ-opioid receptor antagonist UD-030 on methamphetamine-induced conditioned place preference. [PDF]

Neuropsychopharmacol Rep
Although methamphetamine (METH) and other addictive substance use disorders are a major social problem worldwide, appropriate pharmacotherapies have not yet been discovered. The novel nonpeptidic μ‐opioid receptor (MOP)‐selective antagonist UD‐030 dose‐dependently inhibited the acquisition and expression of METH‐induced conditioned place preference ...
Ide S, Iwase N, Arai K, Kojima M, Ushiyama S, Ikeda K.   +5 more
europepmc   +2 more sources